当前位置: 首页 > 期刊 > 《中国实用医药》 > 202023
编号:13818297
不同程度乙肝患者HA、PCⅢ、CⅣ、LN和HBV-DNA水平检测分析(3)
http://www.100md.com 2020年8月15日 《中国实用医药》 202023
     [7] 董福昌, 龍健灵, 林丽卿, 等. 血清肝纤维化指标联合肝生化检测对乙肝患者肝纤维化的评估. 沈阳医学院学报, 2018, 20(3):224-226.

    [8] 周萍, 王聪, 王晓琴, 等. 乙肝患者血清标志物与肝纤维化血清学指标的相关性分析. 现代生物医学进展, 2017, 17(7):1350-1352, 1293.

    [9] Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy-induced hepatitis Breactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology, 2014, 59(6):2092-2100.

    [10] Gane EJ, Deray G, Liaw YF, et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology, 2014, 146(1):138-146.

    [11] Watashi K, Sluder A, Daito T, et al. Cyclosporin A and its analogs in hibit hepatitis B virus entry into cultured hepatocytes throμgh targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology, 2014, 59(5):1726-1737.

    [12] Heidrich B, Yurdayd?n C, Kaba?am G, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology, 2014, 60(1):87-97.

    [收稿日期:2020-03-30], 百拇医药(邝永辉 王志剑 欧丹萍 李雪华)
上一页1 2 3